4D Molecular falls after early-stage trial data for cystic...

2025-12-17 14:02:38 ET More on 4D Molecular Therapeutics 4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential Transcript 4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential - Slideshow 4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies London Healthcare Conference 2025 Transcript 4D Molecular Therapeutics stock rises after pricing $100M offering Seeking Alpha's Quant Rating on 4D Molecular Therapeutics Read the full article on Seeking Alpha For further details see: 4D Molecular falls after early-stage trial data for cystic fibrosis therapy